XOMA's Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences

XOMA’s Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences

Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here